2 results
Approved WMOWill not start
To determine whether aleglitazar reduces cardiovasculair mortality and morbidity (defined as non-fatal myocardial infarction (MI) and non-fatal stroke) in patients with a recent ACS event and type 2 diabetes.
Approved WMOWill not start
The objective of this post market surveillance registry is to assess whether the Imagio OA/US technology for the indication of breast mass/focal finding diagnosis provides performance characteristics that could be used for worldwide clinical…